-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Verve Therapeutics to Neutral, Maintains Price Target to $13.5

Benzinga·06/18/2025 11:54:08
Listen to the news
HC Wainwright & Co. analyst Mitchell Kapoor downgrades Verve Therapeutics (NASDAQ:VERV) from Buy to Neutral and maintains the price target from $13.5 to $13.5.